CYP2D6 and COVID-19: Furthermore, human clinical data suggests that remdesivir is extensively metabolized by CYP2C8, CYP2D6, and CYP3A4 (Yang, 2020) and since studies have shown that these enzymes are dysregulated by inflammation (Dunvald et al., 2022), the PK profile of remdesivir and dexamethasone could be altered by the inflammatory state observed in COVID-19.